

**To:** Grable, Melissa[Grable.Melissa@epa.gov]; Jones, RDavid[Jones.Rdavid@epa.gov]; Friedman, Dana[Friedman.Dana@epa.gov]; Conde, Rosaura[Conde.Rosaura@epa.gov]; Zinn, Nicole[Zinn.Nicole@epa.gov]; Perry, Tracy[Perry.Tracy@epa.gov]; Myers, Tom[Myers.Tom@epa.gov]; Jakob, Avivah[Jakob.Avivah@epa.gov]; Schroeder, Carolyn[Schroeder.Carolyn@epa.gov]  
**Cc:** Anderson, Neil[Anderson.Neil@epa.gov]; Costello, Kevin[Costello.Kevin@epa.gov]; Sherman, Kelly[Sherman.Kelly@epa.gov]; Arrington, Linda[Arrington.Linda@epa.gov]  
**From:** Bloom, Jill  
**Sent:** Tue 4/4/2017 5:25:09 PM  
**Subject:** FW: Chemical Review Meeting 4/20  
[FY17Q3 DRAs for registration review.docx](#)  
[Monthly Chemical Meeting\\_Q2\\_01\\_26\\_17\\_Final.pptx](#)

Hi, everybody,

We've got our marching orders for the next Program Review, which will focus on DRAs. While it is early in the quarter, we need to provide Rick *et al* with summaries of what we know about the risks for chemicals with Q3 DRAs. We might not have real risk assessments yet, but the CRMs assigned to these cases need to contact their EFED and HED team members about what we do know at this time.

I am attaching the list of cases for which we expect risk assessments in Q3 and the slides that we used last time we briefed on DRAs. You can see that for some of the cases, we are expecting HED assessments only, and also we briefed on some of these cases in Q2 (I assume when they were originally supposed to go forward). I have tried to identify the appropriate CRMs for each of the cases needing risk summaries for Program Review, but please check the first attachment and make sure I've got the right people.

We will be asking the CRMs to contact their EFED and HED teams for assistance this week. It would be great if we could put the slides together in the next week (by next Tues., April 11). Billy wants the final draft by 4/17, but we have a bit of work to do before then. Thanks for your assistance.

Melonie and Jill

PS We are also coordinating with AD and BPPD for whatever they plan to present.

**From:** Smith, Charles

**Sent:** Tuesday, April 04, 2017 10:13 AM

**To:** Biscoe, Melanie <Biscoe.Melanie@epa.gov>; Bloom, Jill <Bloom.Jill@epa.gov>

**Cc:** Arrington, Linda <Arrington.Linda@epa.gov>; Guilaran, Yu-Ting <Guilaran.Yu-Ting@epa.gov>; Sherman, Kelly <Sherman.Kelly@epa.gov>; Costello, Kevin <Costello.Kevin@epa.gov>; Anderson, Neil <Anderson.Neil@epa.gov>; Grable, Melissa <Grable.Melissa@epa.gov>

**Subject:** Chemical Review Meeting 4/20

Melanie and Jill,

We did get agreement from Rick yesterday about wanting the first chemical review meeting of the quarter to discuss RAs. I'd recommend contacting HED and EFED asap and giving them a heads up on needing this info. Again, the focus would be on general risk picture and not necessarily specific numbers. RD has mentioned that they will likely have 10 minutes as well again (Cathryn Britton is the point of contact). I'd also touch base with Rose/Jose from AD and Rick mentioned he asked BPPD to start presenting at these meetings as well so you may hear from them.

Based on HED and EFED emails, the following chemicals are expected for DRAs in Q3:

EPTC, Pyrethrins (HED only), Pendimethalin, Cyfluthrins (HED only), Phostebupirim (HED DRA done but not released), Imidacloprid (HED only), Esfenvalerate (HED only), Chlorpropham, Methiocarb, Methomyl (ESA only in April), Metribuzin, Oxamyl, p-Diclorobenzene, Indoxacarb, Prometryn, Oryzalin, Asulam, Permethrin (HED only), gamma- and lambda-Cyhalothrin (HED only), Etofenprox (HED only), Trifloxystrobin

Moved from Q3 to Q4

Thiodicarb, Methomyl (HED only)

Cypermethrin (HED only)

Bifenthrin (HED only)

Buprofezin

Yu-Ting will be out the last two weeks of April so please send me a draft of the slides by COB 4/17. This should allow us enough time to send them around for the divisions to look at. If you have any questions or need any assistance please let me know. Thanks!

Charles “ Billy” Smith

Acting Associate Division Director

Pesticide Reevaluation Division

Office of Pesticide Programs

703-305-0291